Coya Therapeutics, Inc. (COYA)
Automate Your Wheel Strategy on COYA
With Tiblio's Option Bot, you can configure your own wheel strategy including COYA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol COYA
- Rev/Share 0.2204
- Book/Share 1995.7259
- PB 0.0028
- Debt/Equity 0.0
- CurrentRatio 8.8397
- ROIC -0.0006
- MktCap 92154739.0
- FreeCF/Share -169.8922
- PFCF -0.0324
- PE -5.3765
- Debt/Assets 0.0
- DivYield 0
- ROE -0.002
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | COYA | D. Boral Capital | -- | Buy | -- | $15 | Dec. 4, 2024 |
News
Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of …
Read More
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Coya Therapeutics, Inc. (COYA) and Doximity (DOCS) have performed compared to their sector so far this year.
Read More
Coya Therapeutics: Treg Proof-Of-Concept Continues With Interim FTD Data Release
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Positive
Positive interim data by Coya Therapeutics released from 5 patients in an investigator-initiated proof-of-concept study using COYA-302 for the treatment of patients with FTD. An IND filing and phase 2b initiation of COYA-302 to treat FTD patients expected in the 2nd half of 2025. It is said that the 7 major markets for the Frontotemporal Dementia market is expected to reach $596.3 million by 2034.
Read More
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
Published: April 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 144.7% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Coya Therapeutics, Inc. (COYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 149.6% upside potential for Coya Therapeutics, Inc. (COYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Coya Therapeutics, Inc. (COYA)
- IPO Date 2022-12-29
- Website https://www.coyatherapeutics.com
- Industry Biotechnology
- CEO Dr. Arun Swaminathan Ph.D.
- Employees 8